Results 271 to 280 of about 681,445 (387)

Clinical and Technical Predictors of Treatment Success After Coronary Intravascular Lithotripsy in Calcific Coronary Lesions

open access: yesCatheterization and Cardiovascular Interventions, EarlyView.
ABSTRACT Background Intravascular lithotripsy (IVL) is increasingly used to treat coronary artery calcification (CAC). This study aimed to identify clinical and procedural factors associated with IVL treatment success. Methods This retrospective analysis included 454 patients (73 ± 9 years, 75% male) treated with IVL from the multicenter BENELUX‐IVL ...
Martijn J. H. van Oort   +12 more
wiley   +1 more source

30‐Day DAPT in Patients at High Bleeding Risk Undergoing PCI With Biodegradable‐Polymer Sirolimus‐Eluting Ultra‐Thin Stent

open access: yesCatheterization and Cardiovascular Interventions, EarlyView.
ABSTRACT Background There is limited evidence on the safety and efficacy of biodegradable‐polymer sirolimus‐eluting ultra‐thin stent (BP‐SES) in patients at high bleeding risk (HBR) undergoing percutaneous coronary intervention (PCI). Aims This study aims to evaluate the clinical outcomes of HBR patients treated with BP‐SES and ≤ 30‐day dual ...
Andrea Erriquez   +9 more
wiley   +1 more source

Outcomes of percutaneous transhepatic gallbladder drainage versus percutaneous transhepatic biliary drainage for obstructive jaundice. [PDF]

open access: yesPLoS One
Azami T   +9 more
europepmc   +1 more source

The Impact of Underlying Plaque Characteristics Following the Third‐Generation Resorbable Magnesium Scaffold Implantation: An Intravascular OCT Assessment up to 12‐Months

open access: yesCatheterization and Cardiovascular Interventions, EarlyView.
ABSTRACT Background Third‐generation resorbable magnesium scaffold (RMS) was developed with stronger mechanical properties and thinner struts compared to its predecessor. This study aimed to assess the influence of the OCT‐derived underlying plaque characteristics on in‐scaffold late lumen loss (LLL) in patients treated with RMS up to 12‐months ...
Alp Aytekin   +9 more
wiley   +1 more source

Home - About - Disclaimer - Privacy